Sunday, February 22, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
No Result
View All Result
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
No Result
View All Result
No Result
View All Result

A conversation with Dr. Hochman, CEO of Healthcare in Action

Daily Remedy by Daily Remedy
November 7, 2021
in Uncategorized
0
A conversation with Dr. Hochman, CEO of Healthcare in Action

Dr. Hochman leads a new initiative that provides healthcare services to people experiencing homelessness (PEH). The initiative is part of SCAN Group, an organization known for innovative models of patient care.

Healthcare in Action seeks to prove that caring for PEH populations can be a sustainable, non-profit business model that optimizes both economic and clinical outcomes.

To learn more about Dr. Hochman’s previous work in treating PEH populations, please select the link below:

https://www.sciencedirect.com/science/article/pii/S2213076421000403

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Leave a Reply

Your email address will not be published. Required fields are marked *

Videos

This conversation focuses on debunking myths surrounding GLP-1 medications, particularly the misinformation about their association with pancreatic cancer. The speaker emphasizes the importance of understanding clinical study designs, especially the distinction between observational studies and randomized controlled trials. The discussion highlights the need for patients to critically evaluate the sources of information regarding medication side effects and to empower themselves in their healthcare decisions. Takeaways GLP-1 medications are not linked to pancreatic cancer. Peer-reviewed studies debunk misinformation about GLP-1s. Anecdotal evidence is not reliable for general conclusions. Observational studies have limitations in generalizability. Understanding study design is crucial for evaluating claims. Symptoms should be discussed in the context of clinical conditions. Not all side effects reported are relevant to every patient. Observational studies can provide valuable insights but are context-specific. Patients should critically assess the relevance of studies to their own experiences. Engagement in discussions about specific studies can enhance understanding Chapters 00:00 Debunking GLP-1 Medication Myths 02:56 Understanding Clinical Study Designs 05:54 The Role of Observational Studies in Healthcare
Debunking Myths About GLP-1 Medications
YouTube Video DM9Do_V6_sU
Subscribe

2027 Medicare Advantage & Part D Advance Notice

Clinical Reads

BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us

BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us

by Daily Remedy
February 15, 2026
0

Can lowering tau biology translate into a clinically meaningful slowing of decline in people with early symptomatic Alzheimer’s disease? That is the practical question behind BIIB080, an intrathecal antisense therapy designed to reduce production of tau protein by targeting the tau gene transcript. In a phase 1b program originally designed for safety and dosing, investigators later examined cognitive, functional, and global outcomes as exploratory endpoints. The clinical question matters because current disease-modifying options primarily target amyloid, while tau pathology tracks...

Read more

Join Our Newsletter!

Twitter Updates

No Result
View All Result

© 2026 Daily Remedy